US · PODD · MEDICAL - DEVICES
Insulet Corp. (PODD) intrinsic value and stock valuation
$133.17as of 2026-11-21 · Mkt cap 9.23B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Insulet Corp. DCF and intrinsic value
InvestorsCraft values PODD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PODD’s statements →
Insulet Corp. Graham Number
Graham Number: $41.26d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- DexCom, Inc. (DXCM) $79.32
- Biogen Inc. (BIIB) $249.59
- Waters Corporation (WAT) $440.45
- Quest Diagnostics Incorporated (DGX) $258.28
- Koninklijke Philips N.V. (PHG) $28.61
- Labcorp Holdings Inc. (LH) $367.13
- West Pharmaceutical Services, Inc. (WST) $390.30
- STERIS plc (STE) $255.76
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.7B | $1.31B | $1.1B |
| Operating income | $473.8M | $308.9M | $220M | $37.6M | $126M |
| Net income | $247.1M | $418.3M | $206.3M | $4.6M | $16.8M |
| EPSd | $3.44M | $5.66M | $2.8M | $65.8K | $245K |
| Operating cash flow | $569.3M | $430.3M | $145.7M | $119M | -$-68.1M |
| Capital expenditure | -$-191.6M | -$-124.9M | -$-75.6M | -$-157.3M | -$-122.7M |
| Free cash flow | $377.7M | $305.4M | $70.1M | -$-38.3M | -$-190.8M |
| Total assets | $3.19B | $3.09B | $2.59B | $2.25B | $2.05B |
| Total debt | $1.05B | $1.42B | $1.45B | $1.43B | $1.29B |
| Net debt | $334.7M | $468.6M | $798.1M | $808.9M | $494.9M |
| Total equity | $1.52B | $1.21B | $732.7M | $476.4M | $556.3M |
| Cash and short-term investments | $716.1M | $953.4M | $704.2M | $674.7M | $791.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.7B | $1.31B | $1.1B |
| Cost of revenue | $768.2M | $625.9M | $537.2M | $499.7M | $346.7M |
| Gross profit | $1.94B | $1.45B | $1.16B | $805.6M | $752.1M |
| Research and development expenses | $301.1M | $219.6M | $205M | $180.2M | $160.1M |
| Selling, general and administrative expenses | $1.17B | $917.2M | $734.9M | $587.8M | $466M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.47B | $1.14B | $939.9M | $768M | $626.1M |
| Cost and expenses | $2.23B | $1.76B | $1.48B | $1.27B | $972.8M |
| Interest income | $34.7M | $39.5M | $28.6M | $9.3M | $500K |
| Interest expense | $79.7M | $42.7M | $36.2M | $36M | $61.7M |
| Depreciation and amortization | $113.1M | $80.8M | $72.8M | $63.2M | $57.4M |
| Ebitda | $532.3M | $423.7M | $323.6M | $109M | $139.6M |
| Operating income | $473.8M | $308.9M | $220M | $37.6M | $126M |
| Total other income/expenses, net | -$-134.3M | -$-8.7M | -$-5.4M | -$-27.8M | -$-105.5M |
| Income before tax | $339.5M | $300.2M | $214.6M | $9.8M | $20.5M |
| Income tax expense | $92.4M | -$-118.1M | $8.3M | $5.2M | $3.7M |
| Net income | $247.1M | $418.3M | $206.3M | $4.6M | $16.8M |
| Weighted average shares outstanding | $70.4M | $70.1M | $69.8M | $69.4M | $67.7M |
| Weighted average diluted shares outstanding | $71.9M | $73.9M | $73.6M | $69.9M | $68.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $716.1M | $953.4M | $704.2M | $674.7M | $791.6M |
| Net receivables | $516.9M | $365.5M | $359.7M | $205.6M | $161M |
| Inventory | $452.6M | $430.4M | $402.6M | $346.8M | $303.2M |
| Total current assets | $1.89B | $1.87B | $1.57B | $1.3B | $1.32B |
| Property, plant and equipment, net | $863.2M | $759.8M | $692.8M | $625.9M | $546.4M |
| Goodwill and intangible assets | $168.7M | $150M | $150.4M | $127.2M | $76.4M |
| Long-term investments | $20.1M | $5.5M | $0.00 | $15M | $19.3M |
| Total non-current assets | $1.3B | $1.22B | $1.02B | $952.3M | $732.3M |
| Total assets | $3.19B | $3.09B | $2.59B | $2.25B | $2.05B |
| Accounts payable | $75M | $19.8M | $19.2M | $30.8M | $37.7M |
| Short-term debt | $22.2M | $85.9M | $52.9M | $31.1M | $30.1M |
| Deferred revenue | $14M | $12M | $15.4M | $16.1M | $3.5M |
| Total current liabilities | $680.1M | $528.4M | $451.2M | $364.7M | $228.8M |
| Long-term debt | $1.03B | $1.34B | $1.4B | $1.4B | $1.26B |
| Deferred revenue, non-current | $1.5M | $2M | $1.9M | $1.6M | $1.5M |
| Total non-current liabilities | $995.1M | $1.35B | $1.4B | $1.41B | $1.26B |
| Capital lease obligations | $48.9M | $40M | $29.5M | $27.4M | $7.6M |
| Total liabilities | $1.68B | $1.88B | $1.86B | $1.77B | $1.49B |
| Common stock | $100K | $100K | $100K | $100K | $100K |
| Retained earnings | $287.4M | $40.3M | -$-378M | -$-584.3M | -$-649.5M |
| Accumulated other comprehensive income (loss) | $13.2M | -$-13.2M | $8M | $20M | -$-2.2M |
| Total equity | $1.52B | $1.21B | $732.7M | $476.4M | $556.3M |
| Total investments | $20.1M | $5.5M | $53.5M | $65.8M | $19.3M |
| Total debt | $1.05B | $1.42B | $1.45B | $1.43B | $1.29B |
| Net debt | $334.7M | $468.6M | $798.1M | $808.9M | $494.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $247.1M | $418.3M | $206.3M | $4.6M | $16.8M |
| Depreciation and amortization | $90.4M | $80.8M | $72.8M | $63.2M | $57.4M |
| Stock-based compensation | $62.7M | $69.3M | $48.3M | $40.9M | $34.4M |
| Change in working capital | -$-23.1M | -$-17M | -$-190.6M | -$-2.5M | -$-263.6M |
| Accounts receivable | -$-140.2M | -$-10.4M | -$-154.2M | -$-51.8M | -$-71.3M |
| Inventory | -$-10.6M | -$-32.4M | -$-53.6M | -$-49.1M | -$-154.4M |
| Accounts payable | $49.2M | $2.2M | -$-11M | -$-2.4M | -$-15.6M |
| Net cash provided by operating activities | $569.3M | $430.3M | $145.7M | $119M | -$-68.1M |
| Investments in property, plant and equipment | -$-191.6M | -$-134M | -$-109.2M | -$-157.3M | -$-122.7M |
| Acquisitions, net | $0.00 | $0.00 | -$-3M | -$-26M | $0.00 |
| Net cash used for investing activities | -$-222.7M | -$-146.2M | -$-119.4M | -$-191.1M | -$-82.7M |
| Common stock issued | $33.9M | $20.1M | $26.9M | $16.3M | $23.5M |
| Common stock repurchased | -$-59.6M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-595.3M | -$-28.1M | -$-13.6M | -$-40.3M | $40.7M |
| Net change in cash | -$-237.3M | $249.2M | $14.5M | -$-116.7M | -$-115.6M |
| Cash at end of period | $716.1M | $953.4M | $704.2M | $689.7M | $806.4M |
| Operating cash flow | $569.3M | $430.3M | $145.7M | $119M | -$-68.1M |
| Capital expenditure | -$-191.6M | -$-124.9M | -$-75.6M | -$-157.3M | -$-122.7M |
| Free cash flow | $377.7M | $305.4M | $70.1M | -$-38.3M | -$-190.8M |
Line items
Line items
Line items
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- CEO
- Ashley McEvoy
- Employees
- 5.4K
- Beta
- 1.11
Explore
Frequently asked questions
What is the intrinsic value of Insulet Corp. (PODD)?
Insulet Corp. (PODD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PODD undervalued?
PODD trades at a price of $133.17 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.